Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.

[1] Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors.

[1][2][5] The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects.

[6][7] The drug was originated by Pfizer and is under development by Cerevel Therapeutics.

[1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.